Associations - TMB-L - LARVOL VERI

TMB-L TMB-L	Melanoma Melanoma	TMB-L TMB-L	Melanoma Melanoma	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials
TMB-L TMB-L	Follicular Lymphoma Follicular Lymphoma	TMB-L TMB-L	Follicular Lymphoma Follicular Lymphoma	rituximab Sensitive: B - Late Trials	rituximab Sensitive: B - Late Trials
TMB-L TMB-L	Colorectal Cancer CRC	TMB-L TMB-L	Colorectal Cancer CRC	durvalumab + CP-675206 Sensitive: C3 – Early Trials	durvalumab + CP-675206 Sensitive: C3 – Early Trials
TMB-L TMB-L	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	TMB-L TMB-L	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	mitotane Sensitive: C3 – Early Trials	mitotane Sensitive: C3 – Early Trials
TMB-L TMB-L	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	TMB-L TMB-L	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	PD1 inhibitor Resistant: C3 – Early Trials	PD1 inhibitor Resistant: C3 – Early Trials
TMB-L TMB-L	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	TMB-L TMB-L	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	PD-L1 inhibitor Resistant: C3 – Early Trials	PD-L1 inhibitor Resistant: C3 – Early Trials
TMB-L TMB-L	Glioblastoma GBM	TMB-L TMB-L	Glioblastoma GBM	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
TMB-L TMB-L	Non Small Cell Lung Cancer NSCLC	TMB-L TMB-L	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: C3 – Early Trials	atezolizumab Sensitive: C3 – Early Trials
TMB-L TMB-L	Non Small Cell Lung Cancer NSCLC	TMB-L TMB-L	Non Small Cell Lung Cancer NSCLC	durvalumab + CP-675206 Resistant: C3 – Early Trials	durvalumab + CP-675206 Resistant: C3 – Early Trials
TMB-L TMB-L	Pancreatic Cancer Pancreatic Cancer	TMB-L TMB-L	Pancreatic Cancer Pancreatic Cancer	nivolumab + BMS-986227 Sensitive: C3 – Early Trials	nivolumab + BMS-986227 Sensitive: C3 – Early Trials
TMB-L TMB-L	Lung Cancer Lung Cancer	TMB-L TMB-L	Lung Cancer Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
TMB-L TMB-L	Gastric Cancer Gastric Cancer	TMB-L TMB-L	Gastric Cancer Gastric Cancer	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
TMB-L TMB-L	Mast Cell Leukemia Mast Cell Leukemia	TMB-L TMB-L	Mast Cell Leukemia Mast Cell Leukemia	T-lymphocyte cell therapy Sensitive: C3 – Early Trials	T-lymphocyte cell therapy Sensitive: C3 – Early Trials
TMB-L TMB-L	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	TMB-L TMB-L	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials	T-lymphocyte cell therapy Sensitive: C3 – Early Trials
TMB-L TMB-L	Non Small Cell Lung Cancer NSCLC	TMB-L TMB-L	Non Small Cell Lung Cancer NSCLC	nivolumab + HS-110 Sensitive: C3 – Early Trials	nivolumab + HS-110 Sensitive: C3 – Early Trials
TMB-L TMB-L	Neuroendocrine Tumor Neuroendocrine Tumor	TMB-L TMB-L	Neuroendocrine Tumor Neuroendocrine Tumor	toripalimab Sensitive: C3 – Early Trials	toripalimab Sensitive: C3 – Early Trials
TMB-L TMB-L	Colorectal Cancer CRC	TMB-L TMB-L	Colorectal Cancer CRC	bevacizumab Sensitive: C3 – Early Trials	bevacizumab Sensitive: C3 – Early Trials
TMB-L TMB-L	Non Small Cell Lung Cancer NSCLC	TMB-L TMB-L	Non Small Cell Lung Cancer NSCLC	palbociclib + avelumab + axitinib Sensitive: C3 – Early Trials	palbociclib + avelumab + axitinib Sensitive: C3 – Early Trials
TMB-L TMB-L	Triple Negative Breast Cancer Triple Negative Breast Cancer	TMB-L TMB-L	Triple Negative Breast Cancer Triple Negative Breast Cancer	durvalumab Sensitive: C3 – Early Trials	durvalumab Sensitive: C3 – Early Trials
TMB-L TMB-L	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	TMB-L TMB-L	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	trametinib + Torin1 Sensitive: D – Preclinical	trametinib + Torin1 Sensitive: D – Preclinical
TMB-L TMB-L	Gastric Cancer Gastric Cancer	TMB-L TMB-L	Gastric Cancer Gastric Cancer	olaparib Resistant: D – Preclinical	olaparib Resistant: D – Preclinical